News
AKBLF
31.35
NaN%
--
EURneffy 1 mg approved in the UK as the first and only needle-free adrenaline treatment for young children (aged 4 and older, 15–30 kg) at risk of anaphylaxis
Barchart · 06/15 02:00
Anaphylaxis management is falling short in 2026 – EAACI data suggest EURneffy, the only needle-free nasal adrenaline spray, could help close the gap
Barchart · 06/11 02:00
ALK will present data on real world-use of nasal adrenaline and key learnings from 20 years with SLIT-tablets at EAACI 2026
Barchart · 06/04 01:30
Report on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff
Barchart · 06/01 14:20
ALK to present at the Jefferies Global Healthcare Conference in New York
Barchart · 05/29 09:27
ALK-Abello initiated with a Buy at Berenberg
TipRanks · 05/27 08:28
ALK-Abelló Lifts Outlook After Strong Q1 Call
TipRanks · 05/06 00:43
ALK-Abelló A/S reports Q1 results, raises guidance
Seeking Alpha · 05/05 17:06
Three-month interim report (Q1) 2026 (unaudited)
Barchart · 05/04 05:16
ALK upgrades its full-year outlook
Barchart · 05/04 05:09
Invitation to the presentation of ALK’s first quarter 2026 results on Tuesday, 5 May 2026
Barchart · 04/28 09:14
ALK announces successful outcome of phase 2 trial with its tablet for treatment of peanut allergy demonstrating early onset of efficacy
Barchart · 04/20 07:33
neffy® approved as the first needle-free anaphylaxis treatment of adults and children in Canada
Barchart · 04/15 05:07
Report on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff
Barchart · 04/08 15:37
EURneffy 1 mg approved across the EU as the first and only needle-free adrenaline treatment for young children (≥15 kg) at risk of anaphylaxis
Barchart · 03/31 02:01
Annual General Meeting in ALK-Abelló A/S held on 16 March 2026
Barchart · 03/16 12:37
New data reveals 9 in 10 people prefer EURneffy, a needle-free nasal adrenaline spray, over auto-injectors
Barchart · 03/04 04:20
ALK-Abelló Earnings Call Signals Profitable Growth
TipRanks · 02/24 00:02
ALK-Abelló A/S GAAP EPS of $5.40, revenue of $6.31B
Seeking Alpha · 02/20 14:36
Annual General Meeting in ALK-Abelló A/S on 16 March 2026
Barchart · 02/20 07:55
More
Webull provides a variety of real-time AKBLF stock news. You can receive the latest news about Alk-Abello A/S through multiple platforms. This information may help you make smarter investment decisions.
About AKBLF
ALK-Abello A/S is a Denmark-based company active within the pharmaceutical industry. It is engaged in the development and marketing of pharmaceutical products for the treatment, prevention and diagnosis of allergy. Its product portfolio comprises allergy vaccines, emergency treatments and allergy diagnostics products. The Company’s allergy vaccines product offering comprises tablet vaccines, sublingual vaccines and subcutaneous vaccines. Its emergency treatments product offering comprises products for the management of anaphylaxis. Its allergy diagnostics product offering comprises allergen extracts for allergy testing, such as skin-prick tests. The Company operates worldwide through subsidiaries, production units and distributors in such countries as Austria, Canada, France, Italy, the Netherlands, Poland, Spain, Switzerland, the United States and China.